{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:18:09Z","timestamp":1759342689961,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Higher Committee for Education Development in Iraq Ref D-11-296"},{"name":"Iraqi Ministry of Higher Education and Scientific Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The survival rate for patients with ovarian cancer has changed little in the past three decades since the introduction of platinum-based chemotherapy and new drugs are needed. Statins are drugs used for the treatment and prevention of cardiovascular diseases. Recent work from our laboratory has shown that pitavastatin has potential as a treatment for ovarian cancer if dietary geranylgeraniol is controlled. However, relatively high doses of statins are required to induce apoptosis in cancer cells, increasing the risk of myopathy, the most common adverse effect associated with statins. This makes it desirable to identify drugs which reduce the dose of pitavastatin necessary to treat cancer. A drug-repositioning strategy was employed to identify suitable candidates. Screening a custom library of 100 off-patent drugs for synergistic activity with pitavastatin identified prednisolone as the most prominent hit. Prednisolone potentiated the activity of pitavastatin in several assays measuring the growth, survival or apoptosis in several ovarian cancer cells lines. Prednisolone, alone or in some cases in combination with pitavastatin, reduced the expression of genes encoding enzymes in the mevalonate pathway, providing a mechanistic explanation for the synergy.<\/jats:p>","DOI":"10.1038\/s41598-019-46102-1","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T10:03:04Z","timestamp":1562148184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death"],"prefix":"10.1038","volume":"9","author":[{"given":"Marwan Ibrahim","family":"Abdullah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Najim","family":"Abed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0034-6899","authenticated-orcid":false,"given":"Farhat","family":"Khanim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-3375","authenticated-orcid":false,"given":"Alan","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"46102_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer. 11, 719\u2013725 (2011).","journal-title":"Nat. Rev. Cancer."},{"key":"46102_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ctrv.2013.01.005","volume":"39","author":"F Ricci","year":"2013","unstructured":"Ricci, F., Broggini, M. & Damia, G. Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer Treat. Rev. 39, 561\u2013568 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"46102_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer. J. Clin. 66, 7\u201330 (2016).","journal-title":"CA Cancer. J. Clin."},{"key":"46102_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","volume":"60","author":"N Colombo","year":"2006","unstructured":"Colombo, N. et al. Ovarian cancer. Crit. Rev. Oncol. Hematol. 60, 159\u2013179 (2006).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"46102_CR5","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos, P. A. & Matulonis, U. A. PARP inhibitors in ovarian cancer: a trailblazing and transformative journey. Clin. Cancer Res. (2018).","DOI":"10.1158\/1078-0432.CCR-18-1314"},{"key":"46102_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer. 15, 668\u2013679 (2015).","journal-title":"Nat. Rev. Cancer."},{"key":"46102_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3892\/or.2015.3741","volume":"33","author":"AK Altwairgi","year":"2015","unstructured":"Altwairgi, A. K. Statins are potential anticancerous agents (Review). Oncol. Rep. 33, 1019\u20131039 (2015).","journal-title":"Oncol. Rep."},{"key":"46102_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrc.2016.76","volume":"16","author":"PJ Mullen","year":"2016","unstructured":"Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. The interplay between cell signalling and the mevalonate pathway in cancer. Nature Reviews Cancer 16, 718\u2013731 (2016).","journal-title":"Nature Reviews Cancer"},{"key":"46102_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00034-w","volume":"7","author":"E de Wolf","year":"2017","unstructured":"de Wolf, E. et al. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci. Rep. 7, 4 (2017).","journal-title":"Sci. Rep."},{"key":"46102_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ctrv.2018.06.010","volume":"69","author":"MI Abdullah","year":"2018","unstructured":"Abdullah, M. I., de Wolf, E., Jawad, M. J. & Richardson, A. The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug repurposing. Cancer Treat. Rev. 69, 84\u201389 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"46102_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1124\/jpet.107.132217","volume":"324","author":"A Dudakovic","year":"2008","unstructured":"Dudakovic, A. et al. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. J. Pharmacol. Exp. Ther. 324, 1028\u20131036 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"46102_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ygyno.2013.02.003","volume":"129","author":"E Robinson","year":"2013","unstructured":"Robinson, E. et al. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol. Oncol. 129, 417\u2013424 (2013).","journal-title":"Gynecol. Oncol."},{"key":"46102_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","volume":"112","author":"Y Shitara","year":"2006","unstructured":"Shitara, Y. & Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71\u2013105 (2006).","journal-title":"Pharmacol. Ther."},{"key":"46102_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1742-1241.2005.00461.x","volume":"59","author":"RY Mukhtar","year":"2005","unstructured":"Mukhtar, R. Y., Reid, J. & Reckless, J. P. Pitavastatin. Int. J. Clin. Pract. 59, 239\u2013252 (2005).","journal-title":"Int. J. Clin. Pract."},{"key":"46102_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"46102_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2009-0117","volume":"15","author":"J Rodon","year":"2010","unstructured":"Rodon, J., Perez, J. & Kurzrock, R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist 15, 37\u201350 (2010).","journal-title":"Oncologist"},{"key":"46102_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08649-9","volume":"7","author":"MI Abdullah","year":"2017","unstructured":"Abdullah, M. I., Abed, M. N. & Richardson, A. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Sci. Rep. 7, 9 (2017).","journal-title":"Sci. Rep."},{"key":"46102_CR18","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1248\/bpb.b15-00746","volume":"39","author":"M Elsayed","year":"2016","unstructured":"Elsayed, M. et al. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study. Biol. Pharm. Bull. 39, 1238\u20131246 (2016).","journal-title":"Biol. Pharm. Bull."},{"key":"46102_CR19","first-page":"1851","volume":"35","author":"M Rogers","year":"2015","unstructured":"Rogers, M. et al. Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate. Anticancer Res. 35, 1851\u20131859 (2015).","journal-title":"Anticancer Res."},{"key":"46102_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000093006","volume":"70","author":"DR Budman","year":"2006","unstructured":"Budman, D. R. & Calabro, A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70, 147\u2013153 (2006).","journal-title":"Oncology"},{"key":"46102_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2016.03.004","volume":"375","author":"A Gobel","year":"2016","unstructured":"Gobel, A. et al. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. Cancer Lett. 375, 162\u2013171 (2016).","journal-title":"Cancer Lett."},{"key":"46102_CR22","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1158\/0008-5472.CAN-14-0130","volume":"74","author":"A Pandyra","year":"2014","unstructured":"Pandyra, A. et al. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. Cancer Res. 74, 4772\u20134782 (2014).","journal-title":"Cancer Res."},{"key":"46102_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.38","volume":"1","author":"FL Khanim","year":"2011","unstructured":"Khanim, F. L. et al. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer. J. 1, e39 (2011).","journal-title":"Blood Cancer. J."},{"key":"46102_CR24","doi-asserted-by":"crossref","unstructured":"Abed, M. N., Abdullah, M. I. & Richardson, A. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J. Ovarian Res. 9, y (2016).","DOI":"10.1186\/s13048-016-0234-y"},{"key":"46102_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.tiv.2007.03.003","volume":"21","author":"M Goldoni","year":"2007","unstructured":"Goldoni, M. & Johansson, C. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol. In. Vitro. 21, 759\u2013769 (2007).","journal-title":"Toxicol. In. Vitro."},{"key":"46102_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T Chou","year":"2010","unstructured":"Chou, T. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"46102_CR27","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.1128\/MCB.17.12.6906","volume":"17","author":"A Richardson","year":"1997","unstructured":"Richardson, A., Malik, R. K., Hildebrand, J. D. & Parsons, J. T. Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: A role for paxillin tyrosine phosphorylation. Mol. Cell. Biol. 17, 6906\u20136914 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"46102_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).","journal-title":"Nat. Commun."},{"key":"46102_CR29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.18632\/oncoscience.315","volume":"3","author":"N Sundahl","year":"2016","unstructured":"Sundahl, N. et al. Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments. Oncoscience 3, 188\u2013202 (2016).","journal-title":"Oncoscience"},{"key":"46102_CR30","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1111\/j.1476-5381.2009.00465.x","volume":"158","author":"I Campia","year":"2009","unstructured":"Campia, I. et al. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. Br. J. Pharmacol. 158, 1777\u20131786 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"46102_CR31","doi-asserted-by":"publisher","first-page":"22723","DOI":"10.1074\/jbc.M800720200","volume":"283","author":"L Madsen","year":"2008","unstructured":"Madsen, L. et al. Activation of liver X receptors prevents statin-induced death of 3T3-L1 preadipocytes. J. Biol. Chem. 283, 22723\u201322736 (2008).","journal-title":"J. Biol. Chem."},{"key":"46102_CR32","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","volume":"79","author":"PJ Mullen","year":"2010","unstructured":"Mullen, P. J., Luscher, B., Scharnagl, H., Krahenbuhl, S. & Brecht, K. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem. Pharmacol. 79, 1200\u20131209 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"46102_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/13813455.2013.774022","volume":"119","author":"WW Fleuren","year":"2013","unstructured":"Fleuren, W. W. et al. Prednisolone induces the Wnt signalling pathway in 3T3-L1 adipocytes. Arch. Physiol. Biochem. 119, 52\u201364 (2013).","journal-title":"Arch. Physiol. Biochem."},{"key":"46102_CR34","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.bbamcr.2007.01.012","volume":"1773","author":"K Rajalingam","year":"2007","unstructured":"Rajalingam, K., Schreck, R., Rapp, U. R. & Albert, S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773, 1177\u20131195 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"46102_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/1055-9965.EPI-07-0531","volume":"17","author":"A Hoque","year":"2008","unstructured":"Hoque, A., Chen, H. & Xu, X. C. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol. Biomarkers Prev. 17, 88\u201394 (2008).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"46102_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejphar.2011.09.031","volume":"670","author":"YS Tu","year":"2011","unstructured":"Tu, Y. S. et al. Involvement of Chk1-Cdc25A-cyclin A\/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur. J. Pharmacol. 670, 356\u2013364 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"46102_CR37","first-page":"515","volume":"44","author":"AM Giudetti","year":"1998","unstructured":"Giudetti, A. M. & Gnoni, G. V. Short-term effect of dexamethasone on fatty acid and cholesterol synthesis in isolated rat hepatocytes. Biochem. Mol. Biol. Int. 44, 515\u2013521 (1998).","journal-title":"Biochem. Mol. Biol. Int."},{"key":"46102_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1007016403736","volume":"202","author":"M Lambert","year":"1999","unstructured":"Lambert, M. & Bui, N. D. Dexamethasone-induced decrease in HMG-CoA reductase and protein-farnesyl transferase activities does not impair ras processing in AR 4-2J cells. Mol. Cell. Biochem. 202, 101\u2013108 (1999).","journal-title":"Mol. Cell. Biochem."},{"key":"46102_CR39","doi-asserted-by":"crossref","first-page":"72147","DOI":"10.18632\/oncotarget.20046","volume":"8","author":"Y Kobayashi","year":"2017","unstructured":"Kobayashi, Y. et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget 8, 72147\u201372156 (2017).","journal-title":"Oncotarget"},{"key":"46102_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/cr.2008.61","volume":"18","author":"RA DeBose-Boyd","year":"2008","unstructured":"DeBose-Boyd, R. A. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res. 18, 609\u2013621 (2008).","journal-title":"Cell Res."},{"key":"46102_CR41","doi-asserted-by":"publisher","first-page":"18707","DOI":"10.1074\/jbc.R113.479808","volume":"288","author":"LJ Sharpe","year":"2013","unstructured":"Sharpe, L. J. & Brown, A. J. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J. Biol. Chem. 288, 18707\u201318715 (2013).","journal-title":"J. Biol. Chem."},{"key":"46102_CR42","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1073\/pnas.0700899104","volume":"104","author":"A Radhakrishnan","year":"2007","unstructured":"Radhakrishnan, A., Ikeda, Y., Kwon, H. J., Brown, M. S. & Goldstein, J. L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl. Acad. Sci. USA 104, 6511\u20136518 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"46102_CR43","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1073\/pnas.0700907104","volume":"104","author":"LP Sun","year":"2007","unstructured":"Sun, L. P., Seemann, J., Goldstein, J. L. & Brown, M. S. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII proteins. Proc. Natl. Acad. Sci. USA 104, 6519\u20136526 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"46102_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.2000.80.1.361","volume":"80","author":"GJ Schroepfer","year":"2000","unstructured":"Schroepfer, G. J. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 80, 361\u2013554 (2000).","journal-title":"Physiol. Rev."},{"key":"46102_CR45","first-page":"131","volume":"32","author":"K Lee","year":"1991","unstructured":"Lee, K. Bioavailability of Oral Prednisolone. The Seoul. Journal of Medicine 32, 131\u2013137 (1991).","journal-title":"Journal of Medicine"},{"key":"46102_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0065-230X(08)00406-5","volume":"101","author":"RV Sionov","year":"2008","unstructured":"Sionov, R. V., Spokoini, R., Kfir-Erenfeld, S., Cohen, O. & Yefenof, E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv. Cancer Res. 101, 127\u2013248 (2008).","journal-title":"Adv. Cancer Res."},{"key":"46102_CR47","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00280-014-2496-7","volume":"74","author":"H Ishiguro","year":"2014","unstructured":"Ishiguro, H. et al. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemother. Pharmacol. 74, 249\u2013255 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"46102_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.steroids.2016.02.019","volume":"111","author":"KT Lin","year":"2016","unstructured":"Lin, K. T. & Wang, L. H. New dimension of glucocorticoids in cancer treatment. Steroids 111, 84\u201388 (2016).","journal-title":"Steroids"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46102-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:04:58Z","timestamp":1671275098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46102-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46102"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46102-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,7,3]]},"assertion":[{"value":"1 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9632"}}